A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often ...

CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic ...

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care These data demonstrate Roche's commitment to providing options ...

At the AD/PD meeting held last month in Vienna, scientists implicated T lymphocytes—specifically, the cytotoxic, CD8-positive variety—in Alzheimer’s disease. While the modus operandi of these cells in ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105 in a phase 2 clinical trial.

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma.

Peripheral T cell lymphomas (PTCLs) are a group of high grade non-Hodgkin lymphomas (NHL). These lymphomas grow quickly and your treatment starts soon after diagnosis.

A higher prevalence of Akkermansia spp. bacteria in the gut microbiome may improve response to CAR T-cell therapy in patients with B-cell lymphoma.

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said.

But once a tumor becomes established, cytotoxic T-cells become "exhausted" in the hostile tumor microenvironment and unable to effectively attack tumors.